TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: ALPA · data 2026-11-02
Alpa Laboratories Limited
In plain words
Price: 43.8% below its 52-week high of ₹92.5.
Delivery: 71.2% of traded shares were kept for delivery over the last 10 sessions, against 63.9% over the last 60.
Latest results: a net profit of ₹1 cr for the quarter ended Jun 2026 (-91.7% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹111 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | 4.4% |
| Profit growth, 3 years (yearly) | 6.1% |
At a glance
Promoters 57.2% (-0.1 pts in a year), pledged 0.0%, institutions 0.4%.
P/E 25.0, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 8.4%, ROCE 0.7%, operating margin -3.0%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth 6.1% and sales growth 4.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Thin operating margin (-3.0%).
- Slow sales growth (4.4% a year over 3 years).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ALPA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹23.93 crore, up 25.2% YoY and down 23.8% QoQ.
Net profit was ₹0.98 crore, down 91.7% YoY and down 29% QoQ.
Operating margin was 16.5% (2.2% a year ago).
EPS was ₹0.49, down 91.2% YoY and down 29% QoQ.
ALPA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹23.93 करोड़; पिछले साल की तुलना में 25.2% की बढ़त, पिछली तिमाही की तुलना में 23.8% की गिरावट।
शुद्ध मुनाफ़ा: ₹0.98 करोड़; पिछले साल की तुलना में 91.7% की गिरावट, पिछली तिमाही की तुलना में 29% की गिरावट।
ऑपरेटिंग मार्जिन: 16.5% (एक साल पहले 2.2%)।
EPS: ₹0.49; पिछले साल की तुलना में 91.2% की गिरावट, पिछली तिमाही की तुलना में 29% की गिरावट।
ALPAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹23.93 કરોડ; ગયા વર્ષની સરખામણીએ 25.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 23.8% ઘટાડો.
ચોખ્ખો નફો: ₹0.98 કરોડ; ગયા વર્ષની સરખામણીએ 91.7% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 29% ઘટાડો.
ઓપરેટિંગ માર્જિન: 16.5% (એક વર્ષ પહેલાં 2.2%).
EPS: ₹0.49; ગયા વર્ષની સરખામણીએ 91.2% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 29% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
12/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 64.6% over the last 20 sessions vs 54.2% in the 40 before (1.19x); shares delivered per day 0.58x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 13 Aug 26Results Q1 FY27 results: net profit ₹1 cr -4.3% next session
- 23 Jul 26Results Q4 FY26 results: net profit ₹1.4 cr +0.8% next session
- 11 Feb 26Results Q3 FY26 results: net profit ₹1.9 cr -7.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹24 cr | ₹1 cr | -91.7% | -16.5% | 0.49 |
| Mar 2026 | ₹31 cr | ₹1 cr | — | 11.5% | 0.24 |
| Dec 2025 | ₹29 cr | ₹2 cr | -78.7% | 5.2% | 0.9 |
| Sept 2025 | ₹26 cr | ₹0 cr | -98.6% | -8.5% | 0.05 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 57.19% | 57.19% | 57.19% | 57.29% |
| Foreign institutions (FII) | 0.35% | 0.35% | 0.38% | 0.36% |
| Domestic institutions (DII) | 0.07% | 0.07% | — | — |
| Mutual funds | 0.00% | — | — | — |
| Retail investors | 30.28% | 30.37% | 30.42% | 30.77% |
| Number of shareholders | 17,347 | 17,643 | 17,900 | 18,236 |
Common questions
What was Alpa Laboratories Limited's latest quarterly profit?
Alpa Laboratories Limited reported a net profit of ₹1 cr for the quarter ended Jun 2026 (-91.7% on the same quarter a year earlier), on revenue of ₹24 cr.
How much do promoters hold in Alpa Laboratories Limited?
Promoters held 57.19% of Alpa Laboratories Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Alpa Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Alpa Laboratories Limited's P/E ratio?
About 25, based on the last 12 months' earnings and a price of ₹51.99 (data 2026-11-02).
What is the 52-week high and low of Alpa Laboratories Limited?
The 52-week high is ₹92.5 and the 52-week low is ₹46.1.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Alpa Laboratories Limited | ₹51.99 | ₹105 cr | 25 | — | 8.4% | 0.7% | 0.01 | -44.6% |
| Krebs Biochemicals & Industries Ltd. | ₹57.5 | ₹126 cr | — | — | — | -17.3% | — | -17.4% |
| Sotac Pharmaceuticals Limited | ₹111.65 | ₹123 cr | 21.4 | 2.1 | 10.3% | 17.4% | 0.64 | -6.1% |
| Parnax Lab Limited | ₹109.5 | ₹122 cr | 14.1 | — | 13.2% | 18% | 0.87 | +1.4% |
| Makers Laboratories Ltd | ₹197.01 | ₹119 cr | 34 | — | 3.3% | 7.3% | 0.08 | +19.7% |
| Vaishali Pharma Ltd. | ₹6.55 | ₹87 cr | 20 | — | 6.2% | 3.6% | 0.27 | -36.1% |
Compare ALPA with KREBSBIO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ALPA in TickerKhoj →